April 20, 2017
GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Association of Neurology
| Paris, France, April 20, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that an abstract was accepted for an oral presentation at the 2017 Annual Meeting of the American Association of Neurology (AAN) in Boston, MA, April 22-28, 2017.
Please find the full PDF press release attached. gensight_biologics_pr_2017_aan_20170420
Contacts
Source: Gensight |
